ArticleLeukemia2023
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.British journal of haematology · 2024Trial
- Myeloid neoplasm with PDGFRA rearrangement presenting in blast-phase with basophilia.Journal of hematopathology · 2026Article
- Hypereosinophilic syndrome and cerebral watershed infarction.Intensive care medicine · 2026Article
- Article
- Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (FIP1L1::PDGFRA) complicated by Loeffler's endocarditis leading to stroke.BMC neurology · 2026Article
- Article
- Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.Current hematologic malignancy reports · 2026Review
- Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study.The journal of pathology. Clinical research · 2026Article
- A case report and a literature review of Myeloid/Lymphoid Neoplasm with Eosinophilia and PCM1::JAK2 rearrangement representing as B-cell acute lymphoblastic leukemia B-ALL.Annals of hematology · 2026Review
- Targeted Therapy for a RareInternational journal of molecular sciences · 2026Article
- Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.Leukemia · 2026Article
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Detection of leukemia gene fusions on DNA-level through targeted Next-Generation Sequencing.PloS one · 2025Article
- Identification of a novelFrontiers in oncology · 2025Article
- Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- Article
- A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine.Case reports in oncological medicine · 2025Article
- Resistance to imatinib in aFrontiers in oncology · 2025Article
- Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations.Annals of hematology · 2024Article
- Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals.Current hematologic malignancy reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a registry-based analysis of 135 patients with "myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions" (MLN-TK; FIP1L1::PDGFRA, n = 78; PDGFRB, diverse fusions, n = 26; FGFR1, diverse, n = 9; JAK2, diverse, n = 11; ETV6::ABL1, n = 11), we sought to evaluate the disease-defining characteristics. In 81/135 (60%) evaluable patients, hypereosinophilia (>1.5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.